The pros and cons of conducting PD-L1 testing in patients with non-small cell lung cancer. Hossein Borghaei, DO, MS: As far as PD-L1 testing, I’m pretty sure I know how it is at your center because we ...
NORTHFIELD, Ill.--(BUSINESS WIRE)--The College of American Pathologists (CAP) in collaboration with the International Association for the Study of Lung Cancer (IASLC), Pulmonary Pathology Society (PPS ...
NORTHFIELD, Ill.--(BUSINESS WIRE)--The College of American Pathologists (CAP), in collaboration with five other societies, developed a draft evidence-based clinical practice guideline that aims to ...
NEWARK, Del., June 16, 2026 /PRNewswire/ -- The global PD-L1 Biomarker Testing Market is witnessing robust expansion as precision oncology, immunotherapy adoption, and biomarker-driven treatment ...
Mortality within 30 days of receiving checkpoint inhibitor immunotherapy: An Australian multicenter review. % of LA pts I ordered the test 74 31.2 50, 100 % of LA pts another ONC ordered the test 11 ...
Two viewpoint articles published in JAMA Oncology provide opposing opinions on the benefit of testing for programmed death-ligand 1 (PD-L1) expression in patients with non-small-cell lung cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results